ImmunityBio, Inc.
IBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $32 | $26 | $17 | $8 |
| % Growth | 21.3% | 60% | 118.7% | – |
| Cost of Goods Sold | $4 | $0 | $0 | $0 |
| Gross Profit | $28 | $26 | $16 | $8 |
| % Margin | 87.1% | 99.5% | 99.6% | 100% |
| R&D Expenses | $51 | $55 | $48 | $35 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $33 | $42 | $33 | $42 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $84 | $98 | $81 | $77 |
| Operating Income | -$56 | -$71 | -$64 | -$69 |
| % Margin | -173.5% | -269.8% | -390.1% | -919% |
| Other Income/Exp. Net | -$12 | -$21 | -$65 | $10 |
| Pre-Tax Income | -$67 | -$92 | -$130 | -$59 |
| Tax Expense | -$0 | $0 | -$0 | $0 |
| Net Income | -$67 | -$93 | -$130 | -$59 |
| % Margin | -209.8% | -350.3% | -784.9% | -783.4% |
| EPS | -0.071 | -0.1 | -0.15 | -0.08 |
| % Growth | 29% | 33.3% | -87.5% | – |
| EPS Diluted | -0.071 | -0.1 | -0.15 | -0.09 |
| Weighted Avg Shares Out | 947 | 888 | 853 | 733 |
| Weighted Avg Shares Out Dil | 947 | 888 | 853 | 735 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $1 | $1 |
| Interest Expense | $28 | $29 | $29 | $15 |
| Depreciation & Amortization | $4 | $4 | $4 | $4 |
| EBITDA | -$36 | -$60 | -$97 | -$40 |
| % Margin | -111.6% | -225.3% | -588.5% | -531.3% |